Skip to main content
SpringerLink
Log in

Raloxifene: the first selective estrogen receptor modulator for postmenopausal osteoporosis

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998 Apr; 12(4): 335–41

    Article  PubMed  CAS  Google Scholar 

  2. Carlson R. MORE not yet enough for raloxifene and breast cancer prevention. Inpharma 1998 Jun 13; 1141: 13–4

    Google Scholar 

  3. Raloxifene prescribing information. Eli Lilly and Company. Indianapolis, USA, 1997

  4. British National Formulary. No. 35. London: The Pharmaceutical Press, 1998 Mar: 334–5

  5. PDR Generics. 4th ed. Montvale (NJ): Medical Economics, 1998: 71–5

  6. Delmas PD, Bjarnason NH, Mitlak B, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7

    Article  PubMed  CAS  Google Scholar 

  7. Gunness M, Prestwood K, Lu Y, et al. Histomorphometric, bone marker, and bone mineral density response to raloxifene HCl and Premarin in postmenopausal women [abstract no. OR4-2]. The Endocrine Society 79th Annual Meeting: 1997 Jun 11–14 Programme: Minneapolis. Bethesda, Maryland: The Endocrine Society Press 1997: 67

    Google Scholar 

  8. Walsh BW, Kuller LH, Wild RA, et al. The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women [abstract]. Atherosclerosis 1997; 134 (1,2): 182

    Article  Google Scholar 

  9. Huster W, Shah A, Cohen F, et al. Effect of raloxifene on the endometrium in healthy postmenopausal women. The North American Menopause Society 8th Annual Meeting; 1997 Sep 4–6; Boston

  10. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177: 1458–64

    Article  PubMed  CAS  Google Scholar 

  11. Scheele W, Symanowski SM, Neale S, et al. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women [abstract no. P#-246]. The Endocrine Society 79th Annual Meeting: 1997 Jun 11–14 Programme: Minneapolis. Bethesda, Maryland: The Endocrine Society Press 1997: 498

    Google Scholar 

  12. Alendronic acid: effective therapy for postmenopausal osteoporosis. Drugs Ther Perspect 1997 Jul 7; 10(1); 1–5

    Google Scholar 

  13. Prestwood KM. Raloxifene: a viewpoint. Drugs Aging 1998 Apr; 12(4): 342

    Article  Google Scholar 

  14. Hannover Bjarnason N. Raloxifene: a viewpoint. Drugs Aging 1998 Apr; 12(4): 342

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raloxifene: the first selective estrogen receptor modulator for postmenopausal osteoporosis. Drugs Ther. Perspect 12, 1–5 (1998). https://doi.org/10.2165/00042310-199812070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812070-00001

Keywords

Search

Navigation